Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 388

1.

[Vildagliptin suppresses temporal lobe epilepsy by up-regulating glucagon-like peptide-1].

Wen YT, Wu KL, Shi QH.

Nan Fang Yi Ke Da Xue Xue Bao. 2017 Jan 20;37(1):36-43. Chinese.

PMID:
28109096
2.

Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease.

Hussain M, Majeed Babar MZ, Hussain MS, Akhtar L.

Pak J Med Sci. 2016 Nov-Dec;32(6):1396-1401. doi: 10.12669/pjms.326.11133.

3.

Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.

Eom YS, Gwon AR, Kwak KM, Kim JY, Yu SH, Lee S, Kim YS, Park IB, Kim KW, Lee K, Kim BJ.

PLoS One. 2016 Dec 20;11(12):e0168569. doi: 10.1371/journal.pone.0168569.

4.
5.

Effect of race and ethnicity on vildagliptin efficacy: a pooled analysis of phase II and III studies.

Kozlovski P, Fonseca M, Mohan V, Lukashevich V, Odawara M, Paldánius PM, Kothny W.

Diabetes Obes Metab. 2016 Dec 10. doi: 10.1111/dom.12844. [Epub ahead of print]

PMID:
27943546
6.

Anti-inflammatory effects on ischemia/reperfusion-injured lung transplants by the cluster of differentiation 26/dipeptidylpeptidase 4 (CD26/DPP4) inhibitor vildagliptin.

Jang JH, Yamada Y, Janker F, De Meester I, Baerts L, Vliegen G, Inci I, Chatterjee S, Weder W, Jungraithmayr W.

J Thorac Cardiovasc Surg. 2016 Nov 15. pii: S0022-5223(16)31488-X. doi: 10.1016/j.jtcvs.2016.10.080. [Epub ahead of print]

PMID:
27939504
7.

Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.

Kanazawa I, Tanaka KI, Notsu M, Tanaka S, Kiyohara N, Koike S, Yamane Y, Tada Y, Sasaki M, Yamauchi M, Sugimoto T.

Diabetes Res Clin Pract. 2017 Jan;123:9-17. doi: 10.1016/j.diabres.2016.11.010.

PMID:
27914297
8.

Vildagliptin -- Benefit Assessment According to §35a Social Code Book V [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Feb 25.

9.

Hepatic Dipeptidyl Peptidase-4 Controls Pharmacokinetics of Vildagliptin In Vivo.

Asakura M, Fukami T, Nakajima M, Fujii H, Atsuda K, Itoh T, Fujiwara R.

Drug Metab Dispos. 2017 Feb;45(2):237-245. doi: 10.1124/dmd.116.073866.

PMID:
27895112
10.

Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats.

Tanajak P, Pintana H, Siri-Angkul N, Khamseekaew J, Apaijai N, Chattipakorn SC, Chattipakorn N.

J Endocrinol. 2017 Feb;232(2):189-204.

PMID:
27875248
11.

Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.

Tanaka K, Okada Y, Mori H, Miyazaki M, Kuno F, Sonoda S, Sugai K, Hajime M, Kurozumi A, Narisawa M, Torimoto K, Arao T, Mine S, Tanaka Y.

Endocr J. 2016 Nov 12. [Epub ahead of print]

12.

Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells.

Asakura M, Karaki F, Fujii H, Atsuda K, Itoh T, Fujiwara R.

Sci Rep. 2016 Oct 19;6:35633. doi: 10.1038/srep35633.

13.

Acute Toxicity of Vildagliptin.

Hoffmann P, Martin L, Keselica M, Gunson D, Skuba E, Lapadula D, Hayes M, Bentley P, Busch S.

Toxicol Pathol. 2017 Jan;45(1):76-83. doi: 10.1177/0192623316672944.

PMID:
27753637
14.

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with metformin.

Anand A.

J Assoc Physicians India. 2016 Jan;64(1):97. No abstract available.

PMID:
27728173
16.

Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes.

Wu T, Zhang X, Trahair LG, Bound MJ, Little TJ, Deacon CF, Horowitz M, Jones KL, Rayner CK.

J Clin Endocrinol Metab. 2016 Dec;101(12):4769-4778.

PMID:
27598511
17.

[Effectivity and security of vildagliptin as additional treatment for Type 2 diabetes mellitus in real-life conditions in Mexico. EDGE Study subanalysis].

Márquez-Rodríguez E, Brea-Andrea E, Rajmet-Hace VA, Salinas-Salinas J, Mariño-Rojas F.

Gac Med Mex. 2016 Jul-Aug;152(4):457-64. Spanish.

18.

Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.

Park KS, Kwak S, Cho YM, Park KS, Jang HC, Kim SY, Jung HS.

J Diabetes Investig. 2016 Aug 30. doi: 10.1111/jdi.12572. [Epub ahead of print]

19.
20.

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study.

Hassoun AA, Pathan MF, Medlej RC, Alarouj M, Shaltout I, Chawla MS, Knap D, Vaz JA.

Diabetes Metab Syndr Obes. 2016 Jul 26;9:225-31. doi: 10.2147/DMSO.S103692.

Items per page

Supplemental Content

Loading ...
Support Center